Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

Business Wire May 9, 2016

Aurinia Initiates First Clinical Study of Voclosporin for Japan

Business Wire May 9, 2016

Incyte to Present at Upcoming Investor Conferences

Business Wire April 28, 2016

Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio

Business Wire April 15, 2016

Incyte to Report First Quarter Financial Results

Business Wire April 14, 2016

Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)

Business Wire April 6, 2016

Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics

PR Newswire March 31, 2016

Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer

GlobeNewswire March 24, 2016

Incyte's Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AACR Annual Meeting 2016

Business Wire March 16, 2016

Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard

Business Wire February 29, 2016

Julian Baker Buys 2,251,427 Shares of Incyte Corp @$63.50/Share -Form 4

Press Releases February 16, 2016

Benzinga's M&A Chatter for Tuesday February 16, 2016

Press Releases February 16, 2016

Incyte to Present at Upcoming Investor Conferences

Press Releases February 16, 2016

Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Business Wire February 11, 2016

Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer

Business Wire February 11, 2016

Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP

Business Wire January 27, 2016

Incyte to Report Fourth Quarter/Year-End Financial Results

Business Wire January 21, 2016

Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis

PR Newswire January 19, 2016

Incyte Presents Significant Progress in its Development Portfolio

Business Wire January 11, 2016

Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration

Business Wire January 11, 2016